Martin Murphy is a life science investor. He was formerly co-founder and CEO of Syncona, and a director and founding investor of Autolus Therapeutics.
He holds a PhD from the University of Cambridge and an MA in Biochemistry from the University of Oxford.
Martin has been a member of REACT's Independent Strategic Advisory Board since 2026